Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines.
暂无分享,去创建一个
C. Constantinescu | P. Fischer | D. Barrett | P. Gershkovich | K. Wasan | Jong Bong Lee | Atheer Zgair | Jonathan C M Wong | O. Sivak | I. Hennig | J. Mistry | J. Lee | Jonathan C. M. Wong
[1] Anup D. Patel,et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial , 2016, The Lancet Neurology.
[2] B. Burlingame,et al. Fats and Fatty Acids in Human Nutrition , 2016 .
[3] Peter M Fischer,et al. Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and Δ(9)-tetrahydrocannabinol in rat plasma. , 2015, Journal of pharmaceutical and biomedical analysis.
[4] P. Gershkovich,et al. Chain length affects pancreatic lipase activity and the extent and pH-time profile of triglyceride lipolysis. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[5] D. Ju,et al. Biomimetic reassembled chylomicrons as novel association model for the prediction of lymphatic transportation of highly lipophilic drugs via the oral route. , 2015, International journal of pharmaceutics.
[6] Y. Zolotov,et al. Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. , 2015, The International journal on drug policy.
[7] G. Guy,et al. Licensed Cannabis-Based Medicines: Benefits and Risks , 2014 .
[8] Robert Kay,et al. Barriers to access for Canadians who use cannabis for therapeutic purposes. , 2014, The International journal on drug policy.
[9] J. Bronstein,et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders , 2014, Neurology.
[10] T. Collins. Special Report: What Neurologists Are Doing About Medical Marijuana , 2014 .
[11] Thomas Rades,et al. Characterising Lipid Lipolysis and Its Implication in Lipid-Based Formulation Development , 2012, The AAPS Journal.
[12] A. Müllertz,et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. , 2012, Journal of pharmaceutical sciences.
[13] C. Porter,et al. Correction to "targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?". , 2011, Molecular pharmaceutics.
[14] L. James,et al. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? , 2011, Molecular interventions.
[15] C. Porter,et al. Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? , 2010, Molecular pharmaceutics.
[16] J. Tsao,et al. The science of marijuana, 2nd Edition, Leslie Iversen. Oxford University Press, Oxford and New York (2008), ISBN-13: 978-0-19-532824-0, 273 pages, $29.95 , 2009 .
[17] Shimon Amselem,et al. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. , 2009, The Journal of pharmacy and pharmacology.
[18] Arik Dahan,et al. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[19] J. Collet,et al. Adverse effects of medical cannabinoids: a systematic review , 2008, Canadian Medical Association Journal.
[20] K. Mackie,et al. Cannabinoid Receptors: Where They are and What They do , 2008, Journal of neuroendocrinology.
[21] P. Gershkovich,et al. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. , 2007, European Journal of Pharmaceutical Sciences.
[22] A. Hoffman,et al. Use of a Dynamic in Vitro Lipolysis Model to Rationalize Oral Formulation Development for Poor Water Soluble Drugs: Correlation with in Vivo Data and the Relationship to Intra-Enterocyte Processes in Rats , 2006, Pharmaceutical Research.
[23] A. Zuardi. History of cannabis as a medicine: a review. , 2006, Revista brasileira de psiquiatria.
[24] J. Zajicek,et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS) , 2006, International Urogynecology Journal.
[25] P. Gershkovich,et al. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[26] H. Kristensen,et al. Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[27] Christopher J. H. Porter,et al. Intestinal Lymphatic Transport of Halofantrine Occurs After Oral Administration of a Unit-Dose Lipid-Based Formulation to Fasted Dogs , 2003, Pharmaceutical Research.
[28] R. Pertwee. Pharmacological and therapeutic targets for Δ9 tetrahydrocannabinol and cannabidiol , 2004, Euphytica.
[29] J. Zajicek,et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis ( CAMS study ) : multicentre randomised placebo-controlled trial , 2022 .
[30] Franjo Grotenhermen,et al. Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.
[31] Christopher J H Porter,et al. Evaluation of the in‐vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products , 2002, The Journal of pharmacy and pharmacology.
[32] Wayne Hall,et al. Adverse effects of cannabis , 1998, The Lancet.
[33] A. Jacklin,et al. Pain relief with oral cannabinoids in familial Mediterranean fever , 1997, Anaesthesia.
[34] L. Shaw,et al. Bypassing the first-pass effect for the therapeutic use of cannabinoids , 1993, Pharmacology Biochemistry and Behavior.
[35] S. Snider,et al. Controlled clinical trial of cannabidiol in Huntington's disease , 1991, Pharmacology Biochemistry and Behavior.
[36] P. Consroe,et al. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans , 1991, Pharmacology Biochemistry and Behavior.
[37] R. Russell,et al. Role of triglyceride-rich lipoproteins from the liver and intestine in the etiology of postprandial peaks in plasma triglyceride concentration. , 1989, Metabolism: clinical and experimental.
[38] J. Ordovás,et al. Postprandial plasma lipoprotein changes in human subjects of different ages. , 1988, Journal of lipid research.
[39] L. Hollister,et al. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. , 1986, Biomedical & environmental mass spectrometry.
[40] L. Hollister,et al. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. , 1981, Psychopharmacology.
[41] L. Hollister,et al. Plasma delta‐9‐tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking , 1980, Clinical pharmacology and therapeutics.
[42] D. Walczak,et al. Characterization of blood disappearance and tissue distribution of [3H]cannabidiol. , 1980, Biochemical pharmacology.
[43] T. Mikuriya. Marijuana in medicine: past, present and future. , 1969, California medicine.